StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CTXR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.73 | $0.70 | -4.05% | 0.7M |
| 05-18 | $0.57 | $0.53 | -7.51% | 2.6M |
| 05-19 | $0.55 | $0.55 | +0.76% | 0.8M |
| 05-20 | $0.55 | $0.58 | +5.45% | 0.9M |
| 05-21 | $0.57 | $0.67 | +16.54% | 0.7M |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-09-30 | Q2 2022 2022-06-30 | Annual 2021 2021-09-30 | Q2 2021 2021-06-30 |
|---|---|---|---|---|
Revenue | $90.00K | $90.00K | $90.00K | $90.00K |
Operating Income | $-33.32M | $-25.77M | $-23.53M | $-18.33M |
Net Income | $-33.64M | $-25.65M | $-23.05M | $-18.09M |
EPS (Diluted) | $-0.23 | $-0.18 | $-0.23 | $-0.20 |
Total Assets | $114.00M | $120.32M | $142.43M | $146.59M |
Total Liabilities | $10.57M | $9.98M | $9.65M | $9.31M |
Cash & Equivalents | $41.71M | $48.04M | $70.07M | $115.66M |
Free Cash Flow OCF − CapEx | Not available | Not available | $-24.26M | $-18.67M |
Shares Outstanding | 146.21M | 146.13M | 145.98M | 145.98M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
CTXR is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.